Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women The following institutions and principal investigators contributed to this study: Hiroki Koyama, M.D., Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases; Futoshi Akiyama, M.D., Department of Pathology, Japanese Foundation for Cancer Research; Masakazu Toi, M.D., Department of Surgery, Tokyo Metropolitan Hospital; Junichi Kurebayashi, M.D., Department of Endocrine Surgery, Kawasaki Medical School; Eisei Shin, M.D., Department of Surgery, Osaka National Hospital; Reiki Nishimura, M.D., Department of Surgery, Kumamoto City Hospital; Yuichi Iino, M.D., Second Department of Surgery, Gunna University Medical School; Kazuaki Asaishi, M.D., Sapporo Kotoni Breast Clinic; Takao Obara, M.D., Department of Endocrine Surgery, Tokyo Women's Medical College; Masahiko Kanno, M.D., Second Department of Surgery, Fukushima Medical

Autor: Noguchi, Shinzaburo, Kasugai, Tsutomu, Miki, Yoshio, Fukutomi, Takashi, Emi, Mitsuru, Nomizu, Tadashi
Zdroj: Cancer; 15 May 1999, Vol. 85 Issue: 10 p2200-2205, 6p
Abstrakt: The purpose of this investigation was to elucidate the clinicopathologic characteristics of BRCA1- and BRCA2-associated hereditary breast carcinomas (HBCs) in Japanese women. Various clinicopathologic characteristics of HBCs arising in patients with BRCA1 or BRCA2 germline mutations were compared with those of the control group (sporadic breast carcinomas). The mean age at the time of diagnosis of BRCA1-associated HBCs and that of BRCA2-associated HBCs (44 years for both) were significantly younger than that of the control group (54 years) and the incidence of bilateral tumors was significantly higher in the BRCA1-associated HBCs (32%) and BRCA2-associated HBCs (29%) than in the control group (6%). BRCA1-associated HBCs showed a tendency (P = 0.06) toward an increase in solid-tubular type tumors and a significant increase in histologic grade 3 tumors (P < 0.01) and lymphatic invasion positive tumors (P < 0.05) compared with the control group. BRCA1-associated HBCs were significantly more estrogen receptor negative (P < 0.01), c-erb B-2 negative (P < 0.05), and p53 positive (P < 0.01), and they also showed a significant increase in MIB-1 staining grades (P < 0.01) as well as microvessel counts (P < 0.05) compared with the control group. However, there was no significant difference in these parameters between the BRCA2-associated HBCs and the control group. BRCA1-associated HBCs in Japanese women have biologically aggressive phenotypes. However, BRCA2-associated HBCs are without distinctive clinicopathologic features compared with sporadic breast carcinomas. Cancer 1999;85:2200–5. © 1999 American Cancer Society.
Databáze: Supplemental Index
Externí odkaz: